

PRODUCT DATA SHEET

Bioworld Technology CO., Ltd.



CBP20 (R21) Peptide

Cat No.: BS2012P

Background

In eukaryotes, the majority of mRNAs have an m(7)G cap, which is added cotranscriptionally and plays a critical role in many aspects of mRNA metabolism. The effect of the cap on translation is mediated by the initiation factor eIF-4F, whereas the effect on pre-mRNA splicing involves a nuclear complex (CBC). CBC consists of two cap binding proteins, CBP20 and CBP80, which mediate the stimulatory functions of the cap in pre-mRNA splicing, 3' end formation and U snRNA export. The genes CBC1 and CBC2 encode CBP80 and CBP20, respectively. CBP80 comprises three domains, each containing a MIF4G domain. CBP20 has an RNAP fold and associates with the second and third domains of CBP80.

Swiss-Prot

P52298

Applications

Blocking

Specificity

This peptide can be used with studies using BS2012 CBP20 (R21) pAb.

Purification & Purity

Synthetic peptide CBP20 (R21). (Note: the amino acid sequence is proprietary). The purity is > 98%.

Product

1 mg/ml in DI water.

Storage & Stability

Store at 4 °C short term. Aliquot and store at -20 °C long term. Avoid freeze-thaw cycles.

Research Use

For research use only, not for use in diagnostic procedure.

Bioworld Technology, Inc.

1660 South Highway 100, Suite 500 St. Louis Park, MN
55416, USA.

Email: info@bioworlde.com

Tel: 6123263284

Fax: 6122933841

Bioworld technology, co, Ltd.

No 9, weidi road Qixia District Nanjing, 210046,
P, R.China.

Email: info@biogot.com

Tel: +86-025-68037686 Fax: +86-025-68035151